Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nektar Therapeutics reports strong Q1 results and advances pipeline

Nektar Therapeutics demonstrated solid financial performance in Q1 2024, with a positive revenue outlook for the full year.
The company's pipeline strength lies in REZPEG's promising results, NKTR-255's progress, and the advancement of NKTR-0165.
Challenges include patient selection complexities and timing uncertainties, while opportunities exist in therapeutic optimization and pipeline expansion.
Overall, Nektar remains focused on advancing its immunology programs and leveraging its financial stability for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Shares of the U.S.-based pharmaceutical company could be set for a 45% swing as they break out from a classic wedge pattern.

Nektar Therapeutics Stock Poised for Significant Move

SVP & CFO of Nektar Therapeutics Inc (NASDAQ:NKTR) Gil M Labrucherie (insider trades) sold 25,000 shares of NKTR on 07/10/2019 at an average price of $34.57 a share.

Nektar Therapeutics Inc (NKTR) SVP & CFO Gil M Labrucherie Sold $864,250 of Shares

Was last month a turning point in a not-so-good year for shareholders?

Here's Why Nektar Therapeutics Stock Gained 13.6% in June

Recent data from Nektar's Phase II melanoma study of NKTR-214 and Opdivo showed improving depth of response, with an emerging clinical profile that looks competitive if not exciting.

Clinical Data Making A Stronger Case For Nektar Therapeutics

Exelixis

Regeneron Pharmaceuticals

On Wednesday, at the end of the two-day Federal Reserve meeting, Chairman Jerome Powell said the U.S.

3 Health Care Stocks Positioned to Outperform the Market

G1 Therapeutics

Iovance Biotherapeutics

Three biotechs, along with recent IPO Pinterest (PINS), are among our four charts to watch today.

3 Biotechs On the Move

Symantec Corp

Vertex Pharmaceuticals

Stock charts of VRTX, NKTR and SYMC are going to end the trading week knocking on the door of major moves.

3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?

Nektar (NKTR) Down 7% Since Last Earnings Report: Can It Rebound?

Nektar Therapeutics is a volatile stock that took investors on a wild ride. The shares traded on both extremes, thus reflecting the shifting market perception of the company's clinical reporting.

Nektar: Elucidating The Ramifications Of The 2019 ASCO Data

Nektar Therapeutics presented updated ASCO data, which showed an additional 4 melanoma patients achieving a complete response, bringing it to 13 out of 38 patients or 34% complete response rate.

Nektar Comes Back To ASCO 2019 More Invigorated Than Ever With Improved Melanoma Data

Nektar Therapeutics released new data for its NKTR-214-Opdivo cocktail for melanoma.

How Nektar Could Climb Close To Old Highs

Nektar (NKTR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Nektar (NKTR) in Focus: Stock Moves 8.8% Higher

Hecla Mining

Factors including acquisition activity, safe-haven buying, and favorable corporate news boosted these stocks.

Why El Paso Electric, Nektar Therapeutics, and Hecla Mining Jumped Today

Mirati Therapeutics

Biotech stocks jumped Monday after pharmaceutical companies presented some positive drug trial results on experimental medicines that give hope for breakthrough treatments for a number of the world's toughest cancers.

Biotech stocks jump after drugmakers show positive data for potential breakthrough cancer treatments

Promising data suggest the company might be able to raise the bar in melanoma treatments.

Here's Why Nektar Therapeutics Is Soaring Today

Investors want to know what's behind the company's plan to split itself in two.

What Is Nektar Therapeutics' New Game Plan?

Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.

Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary

Due to the significant volatility and market inefficiency, there are stellar investment opportunities in the life sciences sector.

Nektar: Undervalued And A Tremendous Prospect

Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.

Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y

Bristol-Myers

Nektar Therapeutics stock popped Thursday after the company said it would present new data for a Bristol-partnered cancer treatment in June.

This Biotech Stock Is Flying As Cancer Update, Opioid Approval Loom

Nektar's Q1 financial results weren't anything to get excited about. But good things could be on the way for the biotech.

What You'll Want to Know About Nektar Therapeutics' Q1 Earnings Results

Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2019 Results - Earnings Call Transcript

The focus will be on Nektar Therapeutics' (NKTR) pipeline progress when the company reports first-quarter results.

News for Nektar Therapeutics Stock (NKTR)